## Gland Pharma Limited (GLAND) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Gland Pharma Limited (GLAND) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) on November 20, 2020.  It operates in the Pharmaceuticals industry and is positioned as a significant player in the injectables segment.  Further details on its specific market niche within the broader pharmaceutical sector would require additional research beyond the provided data.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,770.00       |                                                                      |
| Percentage Change (PChange) | -0.43%          | Negative change from the previous close.                             |
| Pre-Open Activity          | ₹1,790.00       |  Opened higher than the previous close, indicating potential buying interest. |
| Week High                   | ₹2,220.95       | High reached on August 6, 2024.                                     |
| Week Low                    | ₹1,585.70       | Low reached on October 23, 2024.                                    |
| VWAP                        | ₹1,782.16       | Volume Weighted Average Price.                                        |
| Sector PE                   | 42.35           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 42.35           | Price-to-Earnings ratio for GLAND.                                  |
| Delivery Percentage         | 57.92%          | High delivery percentage suggests a significant portion of trades were genuine investments. |
| Market Depth                | Low              | The provided market depth data (total buy/sell quantities of 0) is incomplete and unreliable for analysis. Further data is needed. |


**3. Financial Performance:**

The provided financial data shows quarterly and annual trends for revenue, expenses, profit after tax, and EPS.  Note that all figures are in INR Lakhs (1 Lakh = 100,000).  The data reveals a fluctuating profit after tax and EPS over the past five quarters.

| Quarter      | Revenue (INR Lakhs) | Expenditure (INR Lakhs) | Profit After Tax (INR Lakhs) | Diluted EPS (INR) |
|--------------|----------------------|--------------------------|-----------------------------|-----------------|
| Q2 FY25 (Sep 24)| 112,079.3             | 74,097.7                 | 28,171                     | 17.1             |
| Q1 FY25 (Jun 24)| 106,051.4             | 76,019.9                 | 22,292.1                    | 13.53            |
| Q4 FY24 (Mar 24)| 122,178.5             | 78,909.7                 | 32,141.1                    | 19.51            |
| Q3 FY24 (Dec 23)| 114,125.1             | 76,949.6                 | 27,680.5                    | 16.81            |
| Q2 FY24 (Sep 23)| 105,178.1             | 70,471.8                 | 25,752.7                    | 15.64            |


**Key Financial Ratios:**  Further analysis requires additional financial statements (balance sheet, cash flow statement) to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and current ratio.  The provided data only allows for a limited assessment of profitability.


**4. Corporate Actions and Announcements:**

* **Dividend:** A dividend of ₹20 per share was declared with an ex-date of August 16, 2024.
* **Announcements:** Recent announcements include analysts' meetings, press releases, and updates regarding shareholders' meetings and changes in management.  The specific content of these announcements requires further review to assess their impact on stock performance.


**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 57.86                       | 42.14      | 0.00                           | 100.00    |
| 31-Dec-2023  | 57.86                       | 42.14      | 0.00                           | 100.00    |
| 31-Mar-2024  | 57.86                       | 42.14      | 0.00                           | 100.00    |
| 30-Jun-2024  | 51.83                       | 48.17      | 0.00                           | 100.00    |
| 30-Sep-2024  | 51.83                       | 48.17      | 0.00                           | 100.00    |

A significant decrease in promoter holding from 57.86% to 51.83% between March 2024 and June 2024 is observed. This warrants further investigation into the reasons behind this change.


**6. Volatility and Risk Assessment:**

The stock shows significant volatility based on the week's high and low.  The CM Annual Volatility of 43.18% (from incomplete market depth data) indicates high risk.  A more comprehensive risk assessment requires historical price data and additional risk metrics (e.g., Beta).


**7. Advantages of Buying the Stock:**

* Relatively high delivery percentage suggests genuine investment interest.
* The company operates in the growing pharmaceuticals sector.
* Dividend payouts indicate a commitment to shareholder returns (though the sustainability of this needs further investigation).


**8. Disadvantages and Risks:**

* High volatility and significant price swings pose substantial risk.
* Inconsistent financial performance over the past five quarters raises concerns.
* The decrease in promoter holding is a negative signal.
* Incomplete market depth data prevents a thorough risk assessment.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The recent price action is uncertain, and the incomplete market depth data makes short-term trading risky.  Waiting for clearer market signals is advisable.

* **Medium-Term (3 to 12 months): Don't Buy.**  The inconsistent financial performance and the decrease in promoter holding raise concerns.  Further investigation into the reasons behind these trends is needed before considering an investment.

* **Long-Term (1 year and beyond): Don't Buy.**  While the pharmaceutical sector offers long-term growth potential, the current financial inconsistencies and the drop in promoter holding outweigh the potential benefits for a long-term investment at this time.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial Health: 4/10 (Inconsistent profitability)
* Market Performance: 6/10 (Moderate price fluctuations, high volatility)
* Volatility and Risk: 3/10 (High volatility, incomplete risk assessment)
* Corporate Actions & Governance: 7/10 (Dividend payouts, but requires further investigation into announcements)
* Shareholding Patterns: 4/10 (Significant decrease in promoter holding)

**Analysis Score (out of 10): 7/10**

* Completeness and Utilization of Data: 7/10 (Some data was incomplete, particularly market depth)
* Accuracy and Clarity of Analysis: 8/10 (Analysis was clear and well-structured, but limited by incomplete data)
* Professional Formatting: 9/10 (Report is well-formatted and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, the recommendation for Gland Pharma Limited (GLAND) is currently "Hold" for the short term, "Don't Buy" for the medium term, and "Don't Buy" for the long term.  The inconsistent financial performance, the decrease in promoter holding, and the high volatility outweigh the positive aspects.  Further investigation into the reasons behind the declining promoter holding and a more complete market depth analysis are crucial before considering any investment.  The incomplete nature of some data significantly limits the confidence in this analysis.  Additional research is strongly recommended before making any investment decisions.
